Treatment with the investigational agent givinostat has the potential to delay disease progression when added to corticosteroid treatment in ambulatory boys with Duchenne muscular dystrophy.
compared with placebo, including reduced decline of muscle function and strength, results from the phase 3 EPIDYS trial show.
DMD is a "devastating disease that has only limited treatment options available," Trudeau noted. "If givinostat is approved by the FDA, it could provide a large number of patients with a daily, orally administered therapeutic that could represent a significant advance in treatment of DMD." Givinostat inhibits histone deacetylases , enzymes that modulate gene and protein expression in muscle.
A total of 118 patients received oral givinostat, and 61 received matching placebo twice daily along with corticosteroid treatment for 72 weeks. They were evaluated every 12 weeks for 72 weeks.Treatment with givinostat was associated with a slower decline in performing the four-stair climb compared with the placebo group , a 17-item rating scale that measures motor function, compared with placebo.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Atogepant for Episodic Migraine Prevention: Phase 3 Data PublishedResults of the ELEVATE trial demonstrating the safety and efficacy of oral atogepant for the prevention of treatment-resistant episodic migraine prevention have now been published.
Baca lebih lajut »
Givinostat Shows Positive Effects in Treating Duchenne Muscular DystrophyResults from the phase 3 EPIDYS trial show that givinostat, a drug for the treatment of Duchenne muscular dystrophy (DMD), has shown positive effects in reducing decline of muscle function and strength compared to placebo. The trial's primary endpoint, the four-stair climb assessment, worsened in both the treatment and placebo groups, but the decline was significantly smaller with givinostat. These findings provide strong support for the use of givinostat in the treatment of DMD. The drug is currently awaiting approval from the US Food and Drug Administration (FDA).
Baca lebih lajut »
Breaking Down Data Silos: How Apache Doris Streamlines Customer Data IntegrationLearn how Apache Doris breaks down data silos for insurance firms, streamlining customer data integration and boosting efficiency.
Baca lebih lajut »
Exploring multiparty computation’s role in the future of blockchain privacyMultiparty computation technology can solve data security and privacy issues by processing encrypted data
Baca lebih lajut »
The Gentlemen Season 2 Gets Cautious But Promising Update From ExecutiveAll the latest movie news, movie trailers & reviews - and the same for TV, too.
Baca lebih lajut »
Virtual reality exposure plus electric brain stimulation offers a promising treatment for PTSDCombining two treatments could be a promising option for people, especially military veterans, whose lives are negatively affected by post-traumatic stress disorder, finds a new study. In a clinical trial conducted among U.S.
Baca lebih lajut »